Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04581343 · ClinicalTrials.gov registry record · Phase 1
A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer (PC) Patients
A Phase 1 study, sponsored by Pancreatic Cancer Action Network.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT04581343 is a Phase 1 study that has completed, run by Pancreatic Cancer Action Network. The registered enrollment target is 10 participants.
The verdict
NCT04581343, a Phase 1 study, has completed, sponsored by Pancreatic Cancer Action Network.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This study combines canakinumab (ACZ885), a high-affinity human anti-interleukin-1β (IL-1β) monoclonal antibody (mAb), and spartalizumab (PDR001), a mAb directed against human Programmed Death-1 (PD-1), with the chemotherapy combination of gemcitabine and nab-paclitaxel. This study will confirm for this 4-drug combination the tolerable doses, the acceptable safety profile, and the dose to be used for a Phase II combination treatment regimen.
Interventions
- DRUG Canakinumab injection; spartalizumab, nab-paclitaxel, gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2020-11-02 |
| Est. Completion | 2023-02-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04581343
The ClinicalTrials.gov registry entry for NCT04581343 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pancreatic Cancer Action Network, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Canakinumab injection; spartalizumab, nab-paclitaxel, gemcitabine is the first listed.
NCT04581343 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04581343 about?
NCT04581343 is a clinical study titled "A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer (PC) Patients". This study combines canakinumab (ACZ885), a high-affinity human anti-interleukin-1β (IL-1β) monoclonal antibody (mAb), and spartalizumab (PDR001), a mAb directed against human Programmed Death-1 (PD-1), with the chemotherapy combination of gemcitabine and nab-paclitaxel. This study will confirm for ...
What is the current status of trial NCT04581343?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2020-11-02. Estimated completion is 2023-02-27.
What interventions are being tested in trial NCT04581343?
The interventions under investigation include: Canakinumab injection; spartalizumab, nab-paclitaxel, gemcitabine (DRUG).
Who is sponsoring clinical trial NCT04581343?
This trial is sponsored by Pancreatic Cancer Action Network, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.